anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A randomized cross-over study and subjects will be randomized to take either the high GI or low GI meal. The sequence of the meal will be generated using an online randomiser generator.During screening administer informed consent.Measure height, weight, waist and hip circumference.Blood draw: Two fingerpricks, 5 minutes apart. 1 X 10ml red tube top to prepare serum. Serum and red platelets into separate microtubes. Serum will be used to analyse fasting blood glucose, lipid profile, C-Reactive Protein (CPR), insulin and apolipoprotein. Red platelets will be stored separately for DNA genotyping. During the study visits,On Day 1, subjects will come to the Centre at around 4:00 pm to have the continuous glucose monitoring (CGMS) system inserted. CGMS will be used to measure 24 hour blood glucose concentrations. The sensor records interstitial blood glucose concentrations every five minutes. This will involve the insertion of a small sensor under the skin in the abdomen, which will be carried out by using a device that produces minimal pain and discomfort.Subjects will have to wait in the laboratory for one hour after insertion for the sensor to be stabilized. After one hour the inserted CGMS sensor will be calibrated against a manual finger-prick blood glucose sample.Manual calibration using finger-prick blood samples will need to be carried out before every meal and before bed in the night. The calibrations before dinner and bed will have to be carried out by the subjects at home.Therefore, the subjects will be provided with a finger-prick blood glucose test kit to take home and instructed on how to correctly use it and measure blood glucose values. Subjects will then consume the standardised dinner at around 7pm.Subjects will be asked to fast overnight and instructed to avoid eating or drinking anything, except water, after 10pm. Subjects will arrived between 8.00am and 8.30am the following morning. Baseline blood samples will be collected. A venous cannula will be inserted and a fasting blood sample collected. Baseline basal metabolic rate will be measured using hood-ventilated indirect calorimetry for 30mins during fasting. Subjects will then consume the test meal. Further venous blood samples will be collected at regular intervals for up to 4hours postprandial. After meal, subjects will enter the hood-ventilated indirect calorimetry and measure post-prandial respiratory quotient for 4 hours. A medium GI lunch will then be provided and the subject can either stay in the centre or return to the centre 4 hours after lunch to remove the CGMS.
Acquired sensorineural hearing loss is characterized by a loss of functioning hair cells in the Organ of Corti, with greater hair cell loss correlating with more severe hearing impairment. Children with sensorineural hearing loss experience difficulty developing normal language which usually leads to poor academic and social development. Currently, there are no reparative therapeutic options available, and treatments are designed to augment the diminished function of the injured Organ of Corti.

Pre-clinical data suggest progenitor cell infusions may enhance intrinsic repair mechanisms in the Organ of Corti which may restore hair cells. This treatment could ultimately lead to hearing improvement. Human umbilical cord blood (hUCB) is an available, autologous, stored progenitor cell population available for potential therapeutic use. The primary objective of this study is to determine the safety of autologous hUCB infusion in children with acquired hearing loss. The secondary objective is to determine if functional, physiologic and anatomic outcomes are improved following hUCB treatment in this patient population.
The heart-benefiting brain-strengthening traditional Chinese medicine is characterized by mainly comprising 30-60 g of astragalus, 15-30 g of kudzu root, 15-30 g of parasitic loranthus, 20-40 g of salvia miltiorrhiza, 9-15 g of raw hawthorn and 6-9 g of ligusticum wallichii, and the addition and the subtraction are carried out according to the change of symptoms and the number of accompanying symptoms: 6 g of cassia twig and 9 g of processed aconite root are added for treating chilly limbs; 12 g of dwarf lilyturf tuber and 15 g of raw fleece-flower root are added for treating the yin deficiency symptoms such as dry mouth, red tongue with little coating and constipation; 30 g of codonopsis pilosula and 6 g of schisandra chinensis are added for patients with obvious qi deficiency symptoms such as tiredness, mental fatigue, short breath and the like; for patients with blood stasis, qi stagnation and obvious pain, 12 g of rhizoma corydalis and 9 g of monkshood are added; for insomnia and dreaminess, 15 g of stir-fried jujube kernel, 30 g of tuber fleeceflower stem and other traditional Chinese medicines are added. The preparation method comprises the following steps: putting the traditional Chinese medicines into a container, adding water, and decocting with slow fire for 20 minutes. Filtering residues, taking juice, and decocting with water. The liquid medicine is mixed and taken about 350 ml, and the liquid medicine is taken warmly after breakfast and supper. Five doses are taken as one treatment course. The prescription is prepared from pure Chinese medicaments, has the effects of benefiting heart, strengthening brain, expanding heart and cerebral vessels, increasing blood volume, reducing blood fat and blood pressure and resisting arrhythmia, achieves the aim of treatment and has no side effect.
Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare [ see Warnings and Precautions (5.1, 5.2, 5.4,  5.6)]. 

Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.

For additional information about overdosage treatment contact a poison control center (1-800-222-1222).
Exercise improves cardiac function and metabolism. Although long-term exercise leads to circulating and micro-environmental metabolic changes, the effect of exercise on protein post-translational lactylation modifications as well as its functional relevance is unclear. Here, we report that lactate can regulate cardiomyocyte changes by improving protein lactylation levels and elevating intracellular N6-methyladenosine RNA-binding protein YTHDF2. The intrinsic disorder region of YTHDF2 but not the RNA m6A-binding activity is indispensable for its regulatory function in influencing cardiomyocyte cell size changes and oxygen glucose deprivation/re-oxygenation (OGD/R)-stimulated apoptosis via upregulating Ras GTPase-activating protein-binding protein 1 (G3BP1). Downregulation of YTHDF2 is required for exercise-induced physiological cardiac hypertrophy. Moreover, myocardial YTHDF2 inhibition alleviated ischemia/reperfusion-induced acute injury and pathological remodeling. Our results here link lactate and lactylation modifications with RNA m6A reader YTHDF2 and highlight the physiological importance of this innovative post-transcriptional intrinsic regulation mechanism of cardiomyocyte responses to exercise. Decreasing lactylation or inhibiting YTHDF2/G3BP1 might represent a promising therapeutic strategy for cardiac diseases.
The present invention is directed to a composition for the conditioning of a dental mineralized surface and/or a dental implant and/or for increasing the hydrophilicity of a dental implant having a metal containing surface. The composition comprises EDTA in a concentration of 21-55% by weight and having a pH of 9.0 or above. The high pH of the composition allows more EDTA to be dissolved and the composition is useful for the conditioning of mineralized dental surfaces and/or surfaces of dental implants. The composition of the invention may thus be used for the conditioning of mineralized dental surfaces and dental implant surfaces in order to remove e.g. biofilm, debris, bacteria, bacterial toxins etc and/or for increasing the hydrophilicity of an implant having a metallic surface. The invention is also directed to a kit comprising the composition of the invention and a device to apply the composition to a surface in need of conditioning.
Capecitabine (Xeloda 4:14. ) 150 mg and 500 mg tablets. Capecitabine will be administered at a dose of 1000 mg/m2 twice daily, for a total daily dose of 2000 mg/m 2. Capecitabine will administered P.O. or per G-tube B.I.D. for 14 days, followed by a one-week rest period in 3-week cycles.
Participants will undergo 80 RT sessions using standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504). Participants will be trained at the Frazier Rehab Institute and remotely to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure threshold load. The training will be initiated with a load equal to 20% of their individual Maximum Inspiratory Pressure (PImax) and Maximum Expiratory Pressure (PEmax) values with progressive increases as tolerated up to 60% of their baseline PImax and PEmax measures. The goal will be to reach the 60% load of PImax and PEmax during the last week of each month of the training.
There is a need to identify accurately prognostic factors that determine the progression of intermediate to late-stage age-related macular degeneration (AMD). Currently, clinicians cannot provide individualised prognoses of disease progression. Moreover, enriching clinical trials with rapid progressors may facilitate delivery of shorter intervention trials aimed at delaying or preventing progression to late AMD. Thus, we performed a systematic review to outline and assess the accuracy of reporting prognostic factors for the progression of intermediate to late AMD. A meta-analysis was originally planned. Synonyms of AMD and disease progression were used to search Medline and EMBASE for articles investigating AMD progression published between 1991 and 2021. Initial search results included 3229 articles. Predetermined eligibility criteria were employed to systematically screen papers by two reviewers working independently and in duplicate. Quality appraisal and data extraction were performed by a team of reviewers. Only 6 studies met the eligibility criteria. Based on these articles, exploratory prognostic factors for progression of intermediate to late AMD included phenotypic features (e.g. location and size of drusen), age, smoking status, ocular and systemic co-morbidities, race, and genotype. Overall, study heterogeneity precluded reporting by forest plots and meta-analysis. The most commonly reported prognostic factors were baseline drusen volume/size, which was associated with progression to neovascular AMD, and outer retinal thinning linked to progression to geographic atrophy. In conclusion, poor methodological quality of included studies warrants cautious interpretation of our findings. Rigorous studies are warranted to provide robust evidence in the future.
In addition to the health fair services with general follow-up, and giving each driver a pedometer with instructions on how to use the devise to track daily step counts, all participants in this group will receive daily healthy living advice and encouraging messages about walking through text messages sent by study staff to participants' cellular phone. Participants will be randomized by envelope provided by Memorial Sloan Kettering's Department of Epidemiology and Biostatistics during an in person meeting after the completion of the 1 month run-in or by phone in case we are unable to meet them in person.
PROBLEM TO BE SOLVED: To obtain a solid carcinoma medicine by including a liposome comprising an n-3 series highly unsaturated fatty acid-containing phospholipid. SOLUTION: This medicine contains a liposome comprising an n-3 series highly unsaturated fatty acid-containing phospholipid as an active ingredient. When the medicine is prepared, every form of the medicine is permitted, but the medicine is preferably topically administered to be concentratively taken in the tumor site, e.g. by a method for injecting the medicine into an artery near to the tumor site or a method for retaining the medicine in the tumor site from a view point for exhibiting an improved excellent effect. The liposome is administered at a daily dose of 5-100 mg/kg. Thereby, the medicine exhibiting the topically excellent anticancer activity and not producing side effects is obtained.
An aqueous solution of an extract of liquorice root is contacted with an anion exchange material, the anion-exchange material is washed with water, the material retained thereon is eluted with a dilute aqueous solution of an acid, and the eluate neutralised with alkali to give a product having a powerful cortisone-like activity.  The neutralised eluate may be mixed with alcohol of at least 90 per cent v/v strength, clarified and evaporated to yield a product constituting about 50 per cent or less by weight of the first residue and possessing substantially all of the cortisone-like activity.  The anion-exchange material may be eluted with dilute hydrochloric acid, and the eluate neutralised with dilute sodium hydroxide or ammonia. The effluent and washings from the anion-exchange treatment may be acidified with e.g. acetic acid, to a pH of about 5.0 and evaporated in vacuo to yield a liquorice extract free from substances possessing cortisone-like activity.  In an example a liquorice extract dissolved in distilled water is filtered and passed through a column of anion exchange material previously prepared by contact with 8 per cent v/v aqueous sodium hydroxide.  The resin is then washed with water until the washings are no longer alkaline to litmus.  The effluent and washings are reserved.  The column is eluted with 1.8 per cent v/v hydrochloric acid and washed with water.  The eluates are combined, made alkaline to litmus with ammonia and evaporated in vacuo.  The residue, which possesses the cortisone-like activity, is mixed with 95 per cent v/v ethyl alcohol, filtered, the residue washed with alcohol and the alcoholic filtrates evaporated in vacuo.  The residue obtained is taken up in absolute alcohol, filtered and the filtrate evaporated to give a purified product.  The effluent and washings from the anion-exchange treatment are made acid with acetic acid to pH 5.0, and concentrated in vacuo to give an extract possessing the flavouring, demulcent and expectorant properties of the initial extract but free from cortisone-like activity.
550,454. Pharmaceutical compositions. LEDERLE LABORATORIES, Inc. July 12, 1941. No. 8841. Convention date, Sept. 25, 1940. [Class 81 (i)] A fungicidal and deodorant composition for application to the skin comprises an aqueous alcoholic solution of a cadmium salt and a wetting agent. Suitable cadmium salts are the chloride, bromide, acetate, salicylate and benzoate. Suitable wetting agents are alcohol sulphates, sulphated fatty acid amides, alkylaryl sulphonates, and sulphonated esters of alcohols and dibasic acids and the salts of these compounds. The sodium salt of the dioctyl esters of sulphosuccinic acid is a preferred wetting agent.
22q11.2 (DiGeorge MIM#188400, Velocardiofacial MIM#192430) syndrome is a hemizygous microdeletion on 22q11.2 of typically 3Mb, encompassing approximately 30 genes and mediated by aberrant homologous recombination and unequal crossing-over events between intrachromosomal flanking low-copy repeats (LCRs). The incidence is 1:4000 live births. While somatic symptoms include congenital cardiovascular and craniofacial abnormalities, recurrent infections and hypocalcemia1 , the most prevalent group of symptoms are neuropsychiatric and include cognitive dysfunction with mild mental retardation, behavioral difficulties and psychosis. The syndrome is associated with a lifetime prevalence of schizophrenia-like illness (phenotypically mostly similar to sporadic schizophrenia) of approximately 25 times that of the general population making the presence of this hemideletion the strongest known risk factor for the development of schizophrenia excepting the presence of a monozygotic twin with the illness. The 22q11 region is implicated in the risk architecture of schizophrenia by several linkage studies and harbors a number of proposed susceptibility genes including genes for Catechol-O-methyltransferase (COMT), proline dehydrogenase (PRODH) and ZDHHC8. The neural basis of these pronounced neurocognitive and psychiatric abnormalities is unknown. The present work proposes to (a) study a group of exceptionally high-functioning, normal intelligence, psychosis-free individuals with 21q11.2 syndrome using a hierarchical multimodal imaging approach to define the intermediate systems level phenotype of the disease combined with deletion mapping techniques and (b) to study the functional effects of single nucleotide polymorphisms in genes in the hemideleted region that have been implicated in schizophrenia, taking advantage of the unique fact that the hemizygous deletion allows immediate construction of molecular haplotypes and of potential epistatic allelic effects. This work is expected to (a) elucidate the pathophysiology of the CNS manifestations of the 22q11.2 syndrome and yield a brain intermediate phenotype that will allow studies in small and atypical deletion individuals in an effort to define individual genes responsible for neurocognitive deficit and increased risk for psychosis, (b) facilitate the identification of functional mechanisms underlying increased risk for schizophrenia for individual susceptibility genes in the deletion and for interacting risk alleles within the deleted locus and (c) prepare the ground for a clinical protocol in which the results from (a) and (b) can be applied to a prospective study evaluating early diagnostic and interventional approaches based on genetic risk and intermediate phenotype ascertainment in this group of patients at high risk for the development of psychosis.
The present invention provides a series of novel polyfluoro-substituted pyrazolopyrimidines or salts thereof. Such compounds are inhibitors of tyrosine kinases (BTK). The compounds can have better kinase inhibition selectivity and drug metabolism property. The invention discloses a preparation method of the compound. The invention also discloses a combined drug which comprises the compound and other targeted drug compositions or other drugs. The optimized combined medicine has a synergistic effect, can better inhibit the survival of tumors than a single targeted medicine, and can cause the complete disappearance of some tumors. Compared with single targeting drugs, the optimized combined drug can better treat drug resistance and cancer recurrence of tumors, and the treatment period is shorter. The invention also relates to a combination compound and a pharmaceutical preparation using the same as an active ingredient, which is safer at a lower dose and has a synergistic effect. The invention also includes methods of using these compounds and their formulations for the treatment and inhibition of autoimmune diseases or disorders, heteroimmune diseases or disorders, inflammatory diseases, and cancers or disorders.
Patients will receive efgartigimod alpha via intravenous infusion at a dose of 10 mg/kg, each infusion lasting approximately 2 hours, on Week 0, 1, 2 and 3. Efgartigimod should be administered no later than the second day after initiation of high-dose intravenous methylprednisolone therapy. This is delivered intravenously at a dosage of 1,000 mg/day for five consecutive days, which is then reduced to 500 mg/day for the next three days, followed by 240 mg/day for another three days, and then 120 mg/day for an additional three days. Subsequently, the treatment shifts to oral prednisone, starting with 60 mg daily for seven days, then decreasing to 50 mg daily for the next seven days, followed by 40 mg daily for another seven days. Afterward, the prednisone dosage is reduced by 5 mg every two weeks until it reaches 10 mg. After Week 4, Inebilizumab to prevent relapse will be introduced according to the indication.
In clinical trials, about 14% (PLATO and PEGASUS) to 21% (THEMIS) of patients treated with ticagrelor developed dyspnea. Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment but led to study drug discontinuation in 0.9% (PLATO), 4.3% (PEGASUS), and 6.9% (THEMIS) of patients. 

In a substudy of PLATO, 199 subjects underwent pulmonary function testing irrespective of whether they reported dyspnea. There was no indication of an adverse effect on pulmonary function assessed after one month or after at least 6 months of chronic treatment.

If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to ticagrelor, no specific treatment is required; continue ticagrelor without interruption if possible. In the case of intolerable dyspnea requiring discontinuation of ticagrelor, consider prescribing another antiplatelet agent.
<P>PROBLEM TO BE SOLVED: To provide a new compound having a proliferation inhibitory activity for cancer cells, and to provide a method for producing the same and a medicinal composition or a food composition comprising the compound.  <P>SOLUTION: The new sesquiterpene compound is represented by formula (I). The compound is collected from a cultivated body of Cordyceps sinensis Sacc. or obtained by synthesis from a known substance 4-acetyl-12,13-epoxy-9-trichothecene-3,15-diol. The medicinal composition or the food composition comprises the resultant compound.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
OBJECTIVE: To analyze the consumption of critical nutrients and other sweeteners, according to the degree of food processing in the population of Antioquia.
METHODS: Cross-Sectional Study. The dietary intake of 4,382 participants of the Perfil Alimentario y Nutricional de Antioquia 2019 (Antioquia Food and Nutrition Profile 2019) was evaluated. Processed foods (PF) and ultra-processed products (UPP) reported by 24-hour recall were classified according to the Nova system. The Nutrient Profile Model (NPM) of the Pan American Health Organization (PAHO) was used. The amount of PF and UPP consumed with excess of critical nutrients related to chronic diseases (CD) was measured. The difference in average intake, the prevalence of excess intake, and the likelihood of inadequacy between groups with and without excess dietary content were assessed.
RESULTS: Nearly 50% of the PF and UPP consumed had excess in at least one critical nutrient. The population consumed daily one or more products with excess in free sugar (73.3%), total fat (75.2%), saturated fat (77.0%), sodium (83.9%), and/or sweeteners (36.8%). Those who consumed products with excessive amounts had a higher intake of total fat (> 5.8%); saturated fat (> 3.8%); and sodium (> 698.7 mg) in adults and adolescents, in children 5-10 years (> 659.2 mg), and in children under 5 years (> 498 mg). Those who consumed products with excessive amounts presented the greatest possibilities of dietary inadequacy.
CONCLUSION: The population of Antioquia that consumes PF and UPP with excessive amounts of free sugars, total fat, saturated fat, sodium, and/or sweeteners presents an unbalanced diet. Reducing the consumption of these products and returning to a natural and/or minimally processed diet may be an effective strategy to achieve the nutrient intake recommendations prioritized by PAHO in the population of Antioquia.